INTRODUCTION: Vascular endothelial growth factors (VEGFs) play a central role in angiogenesis and consequently, in various steps of ovarian carcinogenesis. Gene polymorphisms within the VEGF system have revealed a correlation with prognosis in some malignancies. The aim of the present study was to examine the possible importance of 2 VEGF polymorphisms and VEGF-A expression in ovarian cancer. METHODS: We investigated 2 single nucleotide polymorphisms VEGF +405G/C and VEGF -460C/T by polymerase chain reaction and also analyzed VEGF-A expression by immunohistochemistry in 159 women with ovarian cancer. RESULTS: Vascular endothelial growth factor-A expression revealed a significant correlation with survival in a Cox proportional hazards regression model (P = 0.012). Germline polymorphisms were not correlated with clinicopathological parameters such as stage, type, and histology. Heterozygous genotype in VEGF +405G/C predicted a better survival compared with homozygous genotypes (P = 0.034), and the heterozygous genotype in VEGF -460C/T pointed to the same direction. A multivariate analysis also indicated that heterozygosity of either of the 2 polymorphisms held independent prognostic significance (P = 0.001). CONCLUSIONS: Vascular endothelial growth factor polymorphisms +405G/C and VEGF expression seem to have independent prognostic importance.
INTRODUCTION: Vascular endothelial growth factors (VEGFs) play a central role in angiogenesis and consequently, in various steps of ovarian carcinogenesis. Gene polymorphisms within the VEGF system have revealed a correlation with prognosis in some malignancies. The aim of the present study was to examine the possible importance of 2 VEGF polymorphisms and VEGF-A expression in ovarian cancer. METHODS: We investigated 2 single nucleotide polymorphisms VEGF+405G/C and VEGF-460C/T by polymerase chain reaction and also analyzed VEGF-A expression by immunohistochemistry in 159 women with ovarian cancer. RESULTS:Vascular endothelial growth factor-A expression revealed a significant correlation with survival in a Cox proportional hazards regression model (P = 0.012). Germline polymorphisms were not correlated with clinicopathological parameters such as stage, type, and histology. Heterozygous genotype in VEGF+405G/C predicted a better survival compared with homozygous genotypes (P = 0.034), and the heterozygous genotype in VEGF-460C/T pointed to the same direction. A multivariate analysis also indicated that heterozygosity of either of the 2 polymorphisms held independent prognostic significance (P = 0.001). CONCLUSIONS:Vascular endothelial growth factor polymorphisms +405G/C and VEGF expression seem to have independent prognostic importance.
Authors: Setsuko K Chambers; Mary C Clouser; Amanda F Baker; Denise J Roe; Haiyan Cui; Molly A Brewer; Kenneth D Hatch; Michael S Gordon; Mike F Janicek; Jeffrey D Isaacs; Alan N Gordon; Raymond B Nagle; Heather M Wright; Janice L Cohen; David S Alberts Journal: Clin Cancer Res Date: 2010-11-01 Impact factor: 12.531
Authors: Robert A Burger; Mark F Brady; Michael A Bookman; Bradley J Monk; Joan L Walker; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Gini F Fleming; Peter C Lim; Stephen C Rubin; Noriyuki Katsumata; Sharon X Liang Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: Torben F Hansen; Karen-Lise G Spindler; Rikke F Andersen; Jan Lindebjerg; Steen Kølvraa; Ivan Brandslund; Anders Jakobsen Journal: Cancers (Basel) Date: 2010-06-28 Impact factor: 6.639